December 23, 2025
The White House
announced on Friday that nine drugmakers - Amgen, Bristol Myers Squibb,
Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and
Sanofi - have agreed to lower the costs of their prescription drugs in the
U.S., compared to what they are in other countries.
Also said in the deal was that any new drugs made by these companies will be subject to “most-favored-nation” pricing across the country, including commercial and cash pay markets, as well as Medicare and Medicaid, along with commitments to U.S.-based manufacturing.
“The pharmaceutical manufacturers involved in today’s announcement are committing to invest at least $150 billion collectively in U.S. manufacturing in the near term,” the White House’s announcement said. “Additionally, as part of the agreements, several companies are donating active pharmaceutical ingredients for key products to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to reduce reliance on foreign nations and ensure the United States has an adequate supply of such products in the event of an emergency.”
